CureVac NV (CureVac NV) Accounts Payable : $20.06 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Accounts Payable?

CureVac NV's Accounts Payable for the quarter that ended in Mar. 2024 was $20.06 Mil.

CureVac NV's quarterly Accounts Payable increased from Sep. 2023 ($13.42 Mil) to Dec. 2023 ($50.56 Mil) but then declined from Dec. 2023 ($50.56 Mil) to Mar. 2024 ($20.06 Mil).

CureVac NV's annual Accounts Payable declined from Dec. 2021 ($138.15 Mil) to Dec. 2022 ($72.29 Mil) and declined from Dec. 2022 ($72.29 Mil) to Dec. 2023 ($50.56 Mil).

CureVac NV Accounts Payable Historical Data

The historical data trend for CureVac NV's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV Accounts Payable Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

5.92

21.44

138.15

72.29

50.56

CureVac NV Quarterly Data
	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															16.03	14.54	13.42	50.56	20.06

CureVac NV Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

CureVac NV Accounts Payable Related Terms

Thank you for viewing the detailed overview of CureVac NV's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (CureVac NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.